
| Disease Domain | Count |
|---|---|
| Neoplasms | 12 |
| Infectious Diseases | 3 |
| Nervous System Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 14 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TrkA antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date22 Apr 2024 |
Sponsor / Collaborator |
Start Date27 Sep 2021 |
Sponsor / Collaborator University of Lund [+2] |
Start Date21 Sep 2021 |
Sponsor / Collaborator Vilnius University [+2] |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Compound 11e( Kaunas University of Technology) ( TrkA x c-Met ) | Adenocarcinoma of Lung More | Preclinical |
Compound 9f(Kaunas University of Technology) | Melanoma More | Preclinical |
β-amino acids derivatives ( HER2 x c-Met ) | Head and Neck Neoplasms More | Preclinical |
Compound 11d(Kaunas University of Technology) | Bacterial Infections More | Preclinical |
Compound 9c(Kaunas University of Technology) | Melanoma More | Preclinical |





